Wedoany.com Report-Dec.13, The European Medicines Agency's Committee for Medicinal Products for Human Use recommended on December 12, 2025, expanding the application of Eli Lilly's medication Mounjaro (tirzepatide) to include treatment of type 2 diabetes in children and adolescents aged 10 years and older.

Previously, therapeutic choices for managing blood glucose levels in pediatric patients with type 2 diabetes were primarily restricted to metformin and insulin.

Eli Lilly, along with competitor Novo Nordisk from Denmark, has conducted research on their GLP-1 class medications for potential use in younger age groups.

Novo Nordisk's earlier GLP-1 product, Victoza, holds approval for individuals aged 10 and above with type 2 diabetes. The company's Wegovy formulation supports weight management in those 12 years and older.

Mounjaro, containing tirzepatide, currently holds authorization in Europe for adults whose type 2 diabetes remains inadequately managed. It also has approval for supporting weight reduction in adult patients.

The committee's positive opinion supports extending Mounjaro's indication to patients over 10 years with poorly controlled type 2 diabetes. It may serve as monotherapy where metformin is unsuitable due to intolerance or other factors, or in combination with additional diabetes therapies.

Data from an advanced-phase clinical study demonstrated that Mounjaro assisted participants aged 10 to 17 years with type 2 diabetes in achieving improved blood glucose regulation and body weight reduction.